The inflammasome, a group of immune proteins, prevents early cancer development by controlling stem cell proliferation, according to Weill Cornell Medicine research. By removing tumor necrosis factor (TNF) receptors from stem cells and suppressing cancer genes, it delays malignancy.
Using a mouse model of B-cell lymphoma, researchers found inflammasome activity in bone marrow stroma reduces oncogenic proteins like Ras. Without this process, stem cell proliferation accelerates, fueling tumor growth. The study highlights the inflammasome’s dual role: it promotes inflammation in late-stage cancers but guards against cancer initiation.
Future studies aim to identify the specific stromal cells and mechanisms involved, potentially paving the way for therapies that target its protective effects without enhancing harmful inflammation.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].